Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Clinical trial NCT06282536 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06282536
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Potentially Resectable ALK Positive Non-Small Cell Lung Cancer

Start date: 2024-03-01
Primary completion: 2025-06-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.